KYMR
Kymera Therapeutics, Inc.
Stock
$107.39−2.73 (−2.48%)Close Oct 2, 2026
Income statement
| Line | Last 12 months | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $105M | $39M | $47M | $79M | $47M | $73M | $34M | $2.9M |
| Cost of revenue | $105M | $39M | $47M | $79M | $47M | — | — | — |
| Gross profit | $0 | $0 | $0 | $0 | $0 | — | — | — |
| R&D | $376M | $317M | $240M | $189M | $164M | $137M | $62M | $37M |
| Other operating expenses | — | $33M | $21M | — | — | — | — | — |
| Operating income | −$350M | −$349M | −$262M | −$166M | −$161M | −$101M | −$46M | −$42M |
| Non-operating income | — | $38M | — | — | — | — | — | — |
| Pretax income | — | −$311M | — | — | — | — | — | — |
| Taxes | — | $0 | — | — | — | — | — | — |
| Net income | −$300M | −$311M | −$224M | −$147M | −$155M | −$100M | −$46M | −$41M |
| Diluted EPS | −$3.24 | −$3.69 | −$2.98 | −$2.52 | −$2.87 | −$2.09 | −$3.15 | −$24.28 |
| Diluted shares | — | 84.5M | 75.0M | 58.4M | 53.9M | 48.0M | 17.3M | 1.7M |
| Revenue growth | — | −16.7% | −40.1% | +67.8% | −35.7% | +114.0% | +1,060.0% | — |
| Gross margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Operating margin | −333.5% | −891.1% | −555.8% | −210.6% | −344.4% | −138.0% | −136.1% | −1,438.5% |
| Net margin | −285.3% | −794.0% | −475.6% | −187.0% | −330.6% | −137.6% | −134.0% | −1,405.8% |